CoChat

Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia

Open access
Di Maggio, Rosario, Hsieh, Matthew, Zhao, Xiongce, Calvaruso, Giuseppina, Rigano, Paolo, Renda, Disma, Tisdale, John, Maggio, Aurelio · 2018 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

In sickle cell disease (SCD), hydroxyurea (HU) treatment decreases the number of vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) by increasing fetal hemoglobin (HbF). Data are lacking regarding the frequency of HU dose modification or whether sub-therapeutic doses (<15 mg/kg/day) are beneficial. We reviewed the medical records of 140 patients from 2010 to 2014. The laboratory parameters and SCD complications were compared between the first and last visits based on HU use. Fifty patients (36%) never took HU or suspended HU (“no HU” group). Among patients taking <15 mg/kg/day HU on their first visit, half remained at the same dose, and the other half increased to ≥15 mg/kg/day. Among patients taking ≥15 mg/kg/day, 17% decreased to <15 mg/kg/day, and 83% stayed at ≥15 mg/kg/day. The “no HU” group had fewer episodes of VOC and ACS. Both HU treatment groups had a reduction in both complications (p < 0.0001). This improvement was observed in all SCD phenotypes. The white blood cell (WBC) counts were found to be lower, and HbF increased in both HU groups (p = 0.004, 0.001). The maximal HbF response to HU in HbS/β+-thalassemia was 20%, similar to those observed for HbSS (19%) and HbS/β0-thalassemia (22%). HbS/β+-thalassemia could have a similar disease severity as HbSS or HbS/β0-thalassemia. Patients with HbS/β0-thalassemia or HbS/β+-thalassemia phenotypes responded to HU.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms19030681

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (a,c,e) VOC prevalence at first and last visit based on HU status in patients with HbS/S, HbS/β0-thalassemia and HbS/β+-thalassemia; (b,d,f) ACS prevalence at first and last visit based on HU status in patients with HbS/S, HbS/β0-thalassemia and HbS/β+-thalassemia.
Figure 1 (a,c,e) VOC prevalence at first and last visit based on HU status in patients with HbS/S, HbS/β0-thalassemia and HbS/β+-thalassemia; (b,d,f) ACS prevalence at first and last visit based on HU status in patients with HbS/S, HbS/β0-thalassemia and HbS/β+-thalassemia.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 12

Metadata

Authors
Di Maggio, R., Hsieh, M., Zhao, X., Calvaruso, G., Rigano, P., Renda, D., Tisdale, J., & Maggio, A.
Affiliations
  • Campus of Haematology Franco and Piera Cutino, AOOR Villa Sofia-V. Cervello, 90142 Palermo, Italy
  • National Institute of Diabetes and Digestive and Kidney Diseases (US)
  • National Institutes of Health (US)
  • Ospedale Vincenzo Cervello (IT)
Corresponding author
Maggio, Aurelio
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2018-02-28
Volume
19
Issue
3
Pages
681
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2791021987
Cited by
12
References
33
Citations by year
2025: 1 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 1
FWCI
0.85
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Hematology › Blood groups and transfusion
  • Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
Keywords
hydroxyurea, sickle cell disease, sickle beta-thalassemia, vaso-occlusive crisis, acute chest syndrome, fetal hemoglobin, HbSS, white blood cell count
MeSH terms
Adolescent, Adult, Anemia, Sickle Cell, Antisickling Agents, Child, Child, Preschool, Erythrocyte Indices, Female, Follow-Up Studies, Heart Function Tests, Humans, Hydroxyurea, Infant, Liver Function Tests, Male, Middle Aged, Phenotype, Treatment Outcome, beta-Thalassemia, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia. https://app.cochat.ai/papers/10.3390/ijms19030681
The paper
Di Maggio, R., Hsieh, M., Zhao, X., Calvaruso, G., Rigano, P., Renda, D., Tisdale, J., & Maggio, A. (2018). Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms19030681

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.